Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 452

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 452
---
2024, we filed a universal shelf registration statement on Form S-3(File No. 333-277018)(the “Shelf Registration Statement”), which became effective on April 30, 2024. No securities have yet been sold - 305 -

under the Shelf Registration Statement. We have established, and may in the future establish,
“at-the-market” programs pursuant to which we may offer and sell shares of our common stock pursuant to the Shelf Registration Statement.

Our directors and employees may sell our stock through 10b5-1 trading plans or in the market during open windows under
our insider trading policy without such plans in place. Sales of our common stock by our officers, directors, holders of 5% or more of our capital stock and their respective affiliates, and employees could be perceived negatively by investors or
cause downward pressure on our common stock and cause a reduction in the price of our common stock as a result. We have also registered shares of our common stock that we may issue under our employee equity incentive plans. These shares will be able
to be sold freely in the public market upon issuance.

SEC regulations limit the amount of funds that we can raise during any 12-monthperiod pursuant to a shelf registration statement on Form S-3.

SEC regulations limit the amount that companies with a public float of less than $75 million may raise during any
12-month period pursuant to a shelf registration statement on Form S-3. As of the filing of this proxy statement, we are subject to General Instruction I.B.6 to Form S-3, referred to as the baby shelf rules. Under these regulations, the amount of funds we can raise through primary public offerings of securities in any 12-month period using
a registration statement on Form S-3 is limited to one-third of the aggregate market value of the shares of our common stock held by
non-affiliates of the Company. Therefore, we will be limited in the amount of proceeds we are able to raise by selling shares of our common stock using a Form S-3 until
such time as our public float exceeds $75 million. Furthermore, if we are required to file a new registration statement on another form, it may incur additional costs and be subject to delays due to review by the SEC staff.

Our principal stockholders and management own a significant percentage of our common stock and will be able to exert significant control over matters subject to stockholder approval.

Our executive officers, directors, holders of 5% or more of our capital stock and